RxDoctor Payments Data

Mini Das, MD

Cardiovascular Disease · Louisville, KYNPI 1154329449

Payments from drug & device makers

$1,208in general payments, 2019–2025

Across 67 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$258
  • Johnson & Johnson$164
  • Pfizer$155
  • Medtronic$146
  • Irhythm Technologies, Inc.$73
  • Novartis$69
  • plus $344 from 13 others

What the payments were for

  • Food & beverage$1,18198%
  • Education$272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,208 in reported general payments places this provider in the 30th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$206,207
Medicare patients
1,412
Services billed
3,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban322$312,582
XareltoRivaroxaban123$154,752
EntrestoSacubitril/Valsartan81$65,218
BrilintaTicagrelor19$15,209
Metoprolol Succinate439$7,163
Nebivolol Hcl73$3,822
Diltiazem 24hr Er (Cd)Diltiazem Hcl123$3,015
Potassium Chloride148$2,508
Warfarin Sodium213$2,098
Hydralazine Hcl110$1,952
Losartan Potassium179$1,506
Dilt-XrDiltiazem Hcl34$1,400
Carvedilol156$1,352
Metoprolol Tartrate146$1,265
Bumetanide35$1,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$155$312,582322 claims
Johnson & JohnsonXarelto$164$154,752123 claims
NovartisEntresto$69$65,21881 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 258 cardiovascular disease providers in Kentucky.

Other cardiovascular disease in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →